Sir2 inhibitor - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	Sir2 inhibitor	go back to main search page
Accession:	CHEBI:71181	browse the term
Definition:	An EC 3.5.1.98 (histone deacetylase) inhibitor that interferes with the action of Sir2.
Synonyms:	related_synonym:	Sir2 inhibitors
	xref:	wikipedia.en:Sir2

show annotations for term's descendants Sort by:
Rat (186 ) Mouse (184 ) Human (186 ) Chinchilla (0 ) Bonobo (0 ) Dog (3 ) Squirrel (0 ) Pig (3 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (186)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions

IEP

nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Abca1 protein in kidney]

RGD

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

acetyl-CoA carboxylase alpha

multiple interactions
decreases phosphorylation

ISO
EXP

Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein]
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]
Niacinamide results in decreased phosphorylation of ACACA protein

PMID:18482975 PMID:19071085 PMID:21212096

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

angiotensin I converting enzyme

multiple interactions

ISO

2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA]

NCBI chr10:91,410,129...91,430,246
Ensembl chr10:91,409,819...91,430,942

G

angiotensin converting enzyme 2

multiple interactions

ISO

2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA]; [Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA]

NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596

G

actin alpha 2, smooth muscle

increases expression

EXP

Niacinamide results in increased expression of ACTA2 mRNA; Niacinamide results in increased expression of ACTA2 protein

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

adiponectin, C1Q and collagen domain containing

increases secretion
multiple interactions

ISO
EXP

Niacinamide results in increased secretion of ADIPOQ protein
[Alloxan co-treated with Niacinamide] affects the expression of ADIPOQ protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein]

PMID:17452443 PMID:21439372 PMID:26429928

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

argonaute RISC catalytic component 2

multiple interactions

ISO

Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein]

NCBI chr 7:106,907,209...106,994,124
Ensembl chr 7:106,918,125...106,993,980

G

angiotensin II receptor, type 1a

multiple interactions

EXP
ISO

[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA]

PMID:18420994 PMID:37120126

NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660

G

AKT serine/threonine kinase 1

multiple interactions

EXP
ISO

[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein]
Niacinamide inhibits the reaction [baicalin inhibits the reaction [oxophenylarsine results in decreased phosphorylation of AKT1 protein]]

PMID:37566541 PMID:38865859

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

apoptotic peptidase activating factor 1

multiple interactions

ISO

[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]

NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:27,381,855...27,466,772

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

EXP
ISO

Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of BAX protein]
[Berberine co-treated with Niacinamide] results in increased expression of BAX protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]
Niacinamide results in increased expression of BAX mRNA; Niacinamide results in increased expression of BAX protein

PMID:16168987 PMID:16998810 PMID:25478867 PMID:26712469

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

Bcl-2 binding component 3

multiple interactions
increases expression

ISO

[Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA
Niacinamide results in increased expression of BBC3 mRNA

NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666

G

BCL2, apoptosis regulator

multiple interactions

ISO

[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]
[Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]

PMID:25472572 PMID:25478867 PMID:26712469

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 11

multiple interactions
increases expression

ISO

[Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein]
Niacinamide results in increased expression of BCL2L11 mRNA

PMID:25472572 PMID:26712469

NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695

G

BMI1 proto-oncogene, polycomb ring finger

multiple interactions

ISO

Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein]

NCBI chr17:86,240,683...86,250,044
Ensembl chr17:86,243,491...86,250,024

G

caspase 3

multiple interactions
increases cleavage

EXP
ISO

Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
Niacinamide results in increased cleavage of CASP3 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; resveratrol inhibits the reaction [Niacinamide results in increased cleavage of CASP3 protein]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Niacinamide promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]

PMID:16505238 PMID:24040102 PMID:24962570 PMID:25478867 PMID:26712469

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 9

multiple interactions

EXP
ISO

Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]

PMID:16505238 PMID:25478867 PMID:26712469

Ensembl chr 5:159,391,188...159,409,648

G

catalase

multiple interactions

EXP
ISO

[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein]; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Saponins inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]

PMID:20307516 PMID:21382363 PMID:21439372 PMID:21630391 PMID:22056647 More...

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-C motif chemokine ligand 2

decreases expression

ISO

Niacinamide results in decreased expression of CCL2 protein

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 20

increases expression

ISO

Niacinamide results in increased expression of CCL20 mRNA

NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:91,836,946...91,839,736

G

CD36 molecule

decreases expression

EXP

nicotinamide decreases expression of Cd36 protein in kidney

RGD

NCBI chr 4:18,209,088...18,302,142

G

CD38 molecule

multiple interactions

ISO

CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]

NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505

G

CD40 molecule

multiple interactions

ISO

Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA]

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression
decreases expression

ISO
EXP

Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein]
Niacinamide results in increased expression of CDKN1A protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]
Niacinamide results in decreased expression of CDKN1A protein

PMID:12782109 PMID:22561310 PMID:25478867

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 1B

increases expression
multiple interactions

EXP

Niacinamide results in increased expression of CDKN1B protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

cyclin-dependent kinase inhibitor 2A

multiple interactions

ISO

Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter]

NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248

G

component of inhibitor of nuclear factor kappa B kinase complex

increases activity
multiple interactions

ISO

Niacinamide results in increased activity of CHUK protein
resveratrol inhibits the reaction [Niacinamide results in increased activity of CHUK protein]

NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273

G

collagen type I alpha 1 chain

decreases expression
multiple interactions

ISO
EXP

Niacinamide results in decreased expression of COL1A1 mRNA
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]

PMID:16813520 PMID:25707573

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type I alpha 2 chain

multiple interactions

ISO

Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]]

NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995

G

carnitine palmitoyltransferase 1A

decreases expression

EXP

Nicotinamide decreases expression of Cpt1a protein in kidney of 5/6 nephrectomized rats

RGD

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

cytochrome b-245 alpha chain

multiple interactions
increases expression

EXP

Clofibrate inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]; GW 6471 inhibits the reaction [Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]]; Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]

NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214

G

cytochrome b-245 beta chain

multiple interactions

ISO

2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of CYBB mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of CYBB mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of CYBB mRNA]

NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

EXP

Niacinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA]

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

G

cytochrome P450, family 2, subfamily c, polypeptide 23

multiple interactions

EXP

[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2C23 mRNA]

NCBI chr 1:252,838,427...252,863,081
Ensembl chr 1:252,838,433...252,863,067

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

EXP

[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

EXP

[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

defensin beta 5

multiple interactions

ISO

[Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA

NCBI chr16:77,315,424...77,317,828
Ensembl chr16:77,315,424...77,317,828

G

dicer 1 ribonuclease III

multiple interactions

ISO

Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein]

NCBI chr 6:129,392,298...129,457,252
Ensembl chr 6:129,396,014...129,457,252

G

discs large MAGUK scaffold protein 1

multiple interactions

ISO

[Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; Niacinamide inhibits the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA]

NCBI chr11:82,416,853...82,607,797
Ensembl chr11:82,416,853...82,607,797

G

DNA methyltransferase 1

multiple interactions

ISO

Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein]

NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119

G

eukaryotic translation initiation factor 4E binding protein 1

increases phosphorylation
multiple interactions

ISO

Niacinamide results in increased phosphorylation of EIF4EBP1 protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Niacinamide inhibits the reaction [Resveratrol results in decreased phosphorylation of EIF4EBP1 protein]

PMID:19928762 PMID:20169165

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874

G

ERCC excision repair 6, chromatin remodeling factor

increases abundance
multiple interactions

ISO

ERCC6 gene mutant form results in increased abundance of Niacinamide
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased abundance of Niacinamide]

NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895

G

coagulation factor III, tissue factor

decreases expression

ISO

Niacinamide results in decreased expression of F3 protein

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369

G

fatty acid binding protein 1

multiple interactions

EXP

nicotinamide inhibits the reaction [5/6 nephrectomy decreases the expression of Fabp1 protein in kidney]

RGD

NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:104,744,309...104,753,113

G

Fas ligand

multiple interactions

ISO

CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

EXP

Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of FOS protein]

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

forkhead box O1

multiple interactions

ISO
EXP

Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC1 mRNA]; Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA]
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Niacinamide results in increased expression of and results in increased acetylation of FOXO1 protein
Niacinamide inhibits the reaction [Dexamethasone results in decreased acetylation of FOXO1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]

PMID:16917544 PMID:20181797 PMID:26712469

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

forkhead box O3

multiple interactions

ISO

[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of and results in increased expression of FOXO3 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of FOXO3 protein]; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of FOXO3 protein]; Niacinamide results in increased expression of and results in increased acetylation of FOXO3 protein

PMID:23022493 PMID:25472572 PMID:26712469

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845

G

ferritin heavy chain 1

increases expression

ISO

Niacinamide results in increased expression of FTH1 mRNA; Niacinamide results in increased expression of FTH1 protein

NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

ISO

Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC1 mRNA]

NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033

G

glucose-6-phosphate dehydrogenase

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein]

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

glucagon

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA; Sitagliptin Phosphate inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA]

NCBI chr 3:67,522,489...67,531,533
Ensembl chr 3:67,522,489...67,531,533

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

galactosidase, beta 1

multiple interactions
increases expression

EXP

Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Niacinamide results in increased expression of GLB1 protein

NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:122,963,718...123,036,326

G

glyoxalase 1

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]

NCBI chr20:8,665,061...8,683,095
Ensembl chr20:8,665,061...8,683,191

G

glutamic--pyruvic transaminase

multiple interactions

EXP

[Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of GPT protein]

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione-disulfide reductase

multiple interactions

EXP

[Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in decreased expression of GSR protein]; [Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]

PMID:20307516 PMID:21439372 PMID:32894639

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

glutathione S-transferase, mu 5

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]

NCBI chr 2:198,219,769...198,222,732
Ensembl chr 2:198,219,647...198,222,731

G

glutathione S-transferase pi 1

multiple interactions

EXP

[Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of GSTP1 protein]

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

glycogen synthase 2

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein]

NCBI chr 4:177,096,063...177,137,236
Ensembl chr 4:177,096,063...177,137,236

G

hemoglobin alpha, adult chain 2

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein]

NCBI chr10:15,828,291...15,829,138
Ensembl chr10:15,828,377...15,829,141

G

histone deacetylase 1

multiple interactions

ISO

Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein]

NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:147,138,156...147,165,387

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
decreases expression

EXP

[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]
Nicotinamide decreases expression of Hmgcr protein in kidney of 5/6 nephrectomized rats

CTD
RGD

PMID:20696151 PMID:21212096 PMID:19878707

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533

G

heme oxygenase 1

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

intercellular adhesion molecule 1

multiple interactions

ISO

Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

interferon gamma

multiple interactions

ISO

[Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

insulin-like growth factor binding protein 1

multiple interactions

ISO

Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA]

NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344

G

interleukin 10

multiple interactions

ISO

2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein]; [Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein]

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 18

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL18 mRNA

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 beta

multiple interactions
decreases expression
increases expression

EXP
ISO

[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein; [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL1B mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]
Niacinamide results in decreased expression of IL1B mRNA
Niacinamide results in increased expression of IL1B mRNA

PMID:20307516 PMID:21439372 PMID:22385246 PMID:28322830 PMID:29594315

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 2

multiple interactions

ISO

[Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 6

decreases expression
multiple interactions

ISO
EXP

Niacinamide results in decreased expression of IL6 protein
[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]

PMID:12727023 PMID:20307516 PMID:21439372

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin 1

multiple interactions

EXP

[Niacinamide co-treated with Streptozocin] results in decreased expression of INS1 protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein; [Streptozocin co-treated with Niacinamide] results in decreased secretion of INS1 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased expression of INS1 protein]; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS1 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased secretion of INS1 protein]

PMID:16366736 PMID:19647726 PMID:21382363 PMID:21630391 PMID:25999625 More...

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

insulin 2

multiple interactions

ISO

Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS protein]

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805

G

insulin receptor

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein]

NCBI chr12:5,991,135...6,129,275
Ensembl chr12:5,981,835...6,128,803

G

insulin receptor substrate 2

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein]

NCBI chr16:85,190,310...85,214,543
Ensembl chr16:85,190,111...85,214,543

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

EXP

Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of JUN protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of JUN protein]

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

Kelch-like ECH-associated protein 1

multiple interactions

EXP
ISO

[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]
2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA]; [Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA]; Niacinamide inhibits the reaction [Acetaminophen results in increased expression of KEAP1 protein]

PMID:21439372 PMID:33949241 PMID:37120126

NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042

G

KLF transcription factor 4

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] promotes the reaction [Dronabinol results in increased expression of KLF4 mRNA]

NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592

G

lecithin cholesterol acyltransferase

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]

NCBI chr19:50,744,598...50,748,064
Ensembl chr19:50,744,601...50,748,081

G

luteinizing hormone subunit beta

multiple interactions

EXP

Niacinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein]

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

lipoprotein lipase

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107

G

MAF bZIP transcription factor A

multiple interactions

ISO

Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]

NCBI chr 7:109,313,021...109,315,813
Ensembl chr 7:109,313,121...109,315,760

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

ISO

Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen-activated protein kinase 8

multiple interactions

EXP
ISO

Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of MAPK8 protein]
Niacinamide inhibits the reaction [baicalin inhibits the reaction [oxophenylarsine results in increased phosphorylation of MAPK8 protein]]

PMID:16168987 PMID:38865859

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

MDM2 proto-oncogene

increases expression

ISO

Niacinamide results in increased expression of MDM2 mRNA

NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791

G

microRNA 200a

multiple interactions

ISO

2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A]; [Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A]

NCBI chr 5:171,930,717...171,930,805

G

microRNA 203

multiple interactions

ISO

Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter]

NCBI chr 6:137,020,691...137,020,805

G

MLX interacting protein-like

multiple interactions

EXP

nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Mlxipl protein in kidney]

RGD

NCBI chr12:27,178,158...27,213,675
Ensembl chr12:27,178,158...27,213,660

G

matrix metallopeptidase 9

increases expression
multiple interactions

ISO

Niacinamide results in increased expression of MMP9 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of MMP9 protein]

PMID:24145604 PMID:24962570

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

methionine sulfoxide reductase A

multiple interactions

ISO

Niacinamide inhibits the reaction [resveratrol results in increased expression of MSRA protein]

NCBI chr15:42,514,818...42,853,278
Ensembl chr15:42,527,045...42,853,279

G

mitochondrially encoded cytochrome c oxidase I

increases expression

ISO

Niacinamide results in increased expression of COX1 mRNA; Niacinamide results in increased expression of COX1 protein

NCBI chr MT:5,323...6,867
Ensembl chr MT:5,309...6,853

G

mechanistic target of rapamycin kinase

increases phosphorylation
multiple interactions

ISO

Niacinamide results in increased phosphorylation of MTOR protein
Niacinamide inhibits the reaction [resveratrol results in decreased phosphorylation of MTOR protein]

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

ISO

Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in increased expression of and results in increased localization of MYC protein]

PMID:22028816 PMID:24792773

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

nucleic acid binding protein 2

decreases ubiquitination
increases acetylation
multiple interactions

ISO

Niacinamide results in decreased ubiquitination of NABP2 protein
Niacinamide results in increased acetylation of NABP2 protein
Niacinamide promotes the reaction [trichostatin A results in decreased ubiquitination of NABP2 protein]; Niacinamide promotes the reaction [trichostatin A results in increased acetylation of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in decreased ubiquitination of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in increased acetylation of NABP2 protein]

NCBI chr 7:1,415,491...1,421,113
Ensembl chr 7:1,415,492...1,422,682

G

nicotinamide phosphoribosyltransferase

decreases expression
increases activity
multiple interactions

ISO
EXP

Niacinamide results in decreased expression of NAMPT protein
Niacinamide results in increased activity of NAMPT protein
Niacinamide inhibits the reaction [[Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD]; Niacinamide inhibits the reaction [Acetaminophen results in decreased expression of NAMPT protein]
Niacinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA]
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein

PMID:26712469 PMID:32298659 PMID:33606677 PMID:33949241

NCBI chr 6:55,152,756...55,189,547
Ensembl chr 6:55,151,926...55,189,544

G

nuclear receptor co-repressor 1

decreases expression
multiple interactions

ISO

Niacinamide results in decreased expression of NCOR1 protein
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]

NCBI chr10:47,498,852...47,641,612
Ensembl chr10:47,498,852...47,640,350

G

NADH:ubiquinone oxidoreductase subunit A1

multiple interactions

EXP

Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA1 mRNA]

NCBI chr X:121,289,904...121,293,555
Ensembl chr X:121,289,925...121,293,555

G

NADH:ubiquinone oxidoreductase subunit A13

multiple interactions

EXP

Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 mRNA]; Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 protein]

NCBI chr16:19,560,526...19,567,500
Ensembl chr 7:32,257,006...32,257,492

G

NADH:ubiquinone oxidoreductase subunit A2

multiple interactions

EXP

Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA2 mRNA]

NCBI chr18:28,629,795...28,631,884
Ensembl chr18:28,629,795...28,631,884

G

NFE2 like bZIP transcription factor 2

multiple interactions

EXP
ISO

[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]
2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein]; [Niacinamide co-treated with Acetaminophen] affects the localization of NFE2L2 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein]; Niacinamide inhibits the reaction [Acetaminophen results in decreased expression of NFE2L2 protein]

PMID:21439372 PMID:33949241 PMID:37120126

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor kappa B subunit 1

multiple interactions

EXP

[Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of NFKB1 mRNA]

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

nitric oxide synthase 2

multiple interactions

ISO

Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 mRNA]; Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 protein]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

NADPH oxidase 4

multiple interactions
increases expression

EXP

GW 6471 inhibits the reaction [resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]

NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

ISO

2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA]

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

ISO

[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA

NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041

G

oxoglutarate dehydrogenase

multiple interactions

ISO

Niacinamide inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of OGDH protein]

NCBI chr14:85,363,949...85,431,405
Ensembl chr14:85,364,014...85,432,271

G

poly (ADP-ribose) polymerase 1

multiple interactions
decreases activity
increases cleavage
increases expression

EXP
ISO

Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of PARP1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased activity of PARP1 protein]
Niacinamide results in decreased activity of PARP1 protein
Niacinamide results in increased cleavage of PARP1 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Niacinamide inhibits the reaction [baicalin inhibits the reaction [oxophenylarsine results in increased cleavage of PARP1 protein]]; Niacinamide inhibits the reaction [sodium arsenite results in decreased expression of PARP1 protein]
Niacinamide results in increased expression of PARP1 mRNA; Niacinamide results in increased expression of PARP1 protein

PMID:16168987 PMID:19288225 PMID:26712469 PMID:29143419 PMID:36958258 More...

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

pyruvate dehydrogenase kinase 1

multiple interactions

ISO

Niacinamide inhibits the reaction [baicalin inhibits the reaction [oxophenylarsine results in decreased phosphorylation of PDK1 protein]]

NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:77,113,473...77,144,145

G

pyruvate dehydrogenase kinase 4

multiple interactions

EXP

Niacinamide inhibits the reaction [Dexamethasone results in increased expression of PDK4 protein]

NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:34,556,330...34,568,381

G

pyruvate dehydrogenase phosphatase catalytic subunit 1

multiple interactions

EXP

Niacinamide inhibits the reaction [Dexamethasone results in increased phosphorylation of PDP1 protein]

NCBI chr 5:30,245,699...30,252,494
Ensembl chr 5:30,242,704...30,253,960

G

paired-like homeodomain 2

increases expression

ISO

Niacinamide results in increased expression of PITX2 mRNA; Niacinamide results in increased expression of PITX2 protein

NCBI chr 2:220,391,417...220,411,588
Ensembl chr 2:220,391,888...220,411,591

G

peripheral myelin protein 22

multiple interactions

ISO

Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of and results in decreased localization of PMP22 protein]

NCBI chr10:48,294,932...48,324,941
Ensembl chr10:48,297,437...48,324,940

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

ISO
EXP

Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PPARG protein]
[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein]

PMID:22539994 PMID:37566541

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

PPARG coactivator 1 alpha

increases acetylation
multiple interactions

ISO
EXP

Niacinamide results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]

PMID:19071085 PMID:23422569 PMID:23891692

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

protein kinase AMP-activated catalytic subunit alpha 1

multiple interactions

ISO

Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA1 protein]

NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:55,967,351...56,003,450

G

protein kinase AMP-activated catalytic subunit alpha 2

multiple interactions

ISO

Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA2 protein]

NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:125,042,179...125,108,324

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

ISO

Niacinamide results in increased expression of PTGS2 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PTGS2 protein]

PMID:24145604 PMID:24962570

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

glycogen phosphorylase L

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein]

NCBI chr 6:94,433,558...94,476,219
Ensembl chr 6:94,426,346...94,476,269

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

EXP
ISO

[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Metformin inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Salicylic Acid inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]
Niacinamide results in increased acetylation of and results in increased phosphorylation of RELA protein; resveratrol inhibits the reaction [Niacinamide results in increased phosphorylation of and results in increased acetylation of RELA protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein]; [Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein]; Niacinamide inhibits the reaction [Resveratrol results in decreased expression of RELA protein modified form]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]

PMID:20307516 PMID:21439372 PMID:22717288 PMID:23406761 PMID:23735732 More...

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

ribosomal protein S6

multiple interactions

ISO

[Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein

NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566

G

RUNX family transcription factor 2

decreases expression
multiple interactions
increases expression

ISO
EXP

Niacinamide results in decreased expression of RUNX2 mRNA; Niacinamide results in decreased expression of RUNX2 protein
resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein]
Niacinamide results in increased expression of RUNX2 mRNA

PMID:16813520 PMID:22539994

NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027

G

SR-related CTD-associated factor 1

increases expression

EXP

nicotinamide increases expression of Scaf1 protein in kidney

RGD

NCBI chr 1:104,621,927...104,635,161
Ensembl chr 1:104,621,927...104,635,032

G

SREBF chaperone

increases expression

IEP

nicotinamide increases expression of Scap protein in kidney of 5/6 nephrectomized rat

RGD

NCBI chr 8:119,184,366...119,239,086
Ensembl chr 8:119,184,438...119,239,075

G

scavenger receptor class B, member 1

decreases expression

EXP

nicotinamide inhibits the reaction [5/6 nephrectomy increases the expression of Scarb1 protein in kidney]

RGD

NCBI chr12:36,957,302...37,023,982
Ensembl chr12:36,957,496...37,023,980

G

SHC adaptor protein 1

multiple interactions
increases expression

ISO

Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein]
Niacinamide results in increased expression of SHC1 mRNA; Niacinamide results in increased expression of SHC1 protein

PMID:21778425 PMID:24557422

NCBI chr 2:177,135,649...177,147,257
Ensembl chr 2:177,135,659...177,147,914

G

sirtuin 1

multiple interactions
decreases expression
decreases activity

ISO
EXP

[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol; Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA]
Niacinamide results in decreased expression of SIRT1 mRNA; Niacinamide results in decreased expression of SIRT1 protein
[Niacinamide co-treated with Resveratrol] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Fructose; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Metformin; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Resveratrol; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Salicylic Acid; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA; [Resveratrol co-treated with Niacinamide] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of and results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]; Niacinamide inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 mRNA]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of CXCL8 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased susceptibility to Hydrogen Peroxide; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]

PMID:16366736 PMID:17103016 PMID:18420994 PMID:18482975 PMID:18681908 More...

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

sirtuin 2

decreases activity
multiple interactions

ISO

Niacinamide results in decreased activity of SIRT2 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein

PMID:17341628 PMID:26712469

NCBI chr 1:93,181,472...93,204,499
Ensembl chr 1:93,181,224...93,204,499

G

sirtuin 3

multiple interactions

ISO

[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein; Niacinamide inhibits the reaction [baicalin inhibits the reaction [oxophenylarsine results in decreased expression of SIRT3 protein]]

PMID:26712469 PMID:38865859

NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076

G

solute carrier family 2 member 4

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein]; Niacinamide inhibits the reaction [Letrozole results in decreased expression of SLC2A4 mRNA]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein]

PMID:32298659 PMID:37566541

NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270

G

solute carrier organic anion transporter family, member 1a4

affects abundance

ISO

SLCO1A4 protein affects the abundance of Niacinamide

NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816

G

SMAD family member 3

increases phosphorylation
increases expression

EXP

Niacinamide results in increased phosphorylation of SMAD3 protein
Niacinamide results in increased expression of SMAD3 mRNA

NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324

G

SMAD family member 7

decreases expression

EXP

Niacinamide results in decreased expression of SMAD7 mRNA; Niacinamide results in decreased expression of SMAD7 protein

NCBI chr18:71,263,508...71,291,849
Ensembl chr18:71,263,508...71,291,849

G

synaptosome associated protein 23

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA]

NCBI chr 3:127,966,184...127,999,929
Ensembl chr 3:127,967,886...127,998,067

G

superoxide dismutase 1

multiple interactions

EXP
ISO

[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein; Dronabinol promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein]; [Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein]

PMID:31081965 PMID:37120126

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

superoxide dismutase 2

multiple interactions

EXP
ISO

Niacinamide inhibits the reaction [resveratrol results in increased expression of SOD2 mRNA]
Niacinamide inhibits the reaction [baicalin inhibits the reaction [oxophenylarsine results in decreased activity of SOD2 protein]]; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SOD2 protein]

PMID:23891692 PMID:25472572 PMID:38865859

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

SRY-box transcription factor 9

decreases expression
multiple interactions

ISO

Niacinamide results in decreased expression of SOX9 protein
4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]; resveratrol inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]

NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250

G

sequestosome 1

multiple interactions

ISO

Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

sterol regulatory element binding transcription factor 1

multiple interactions

ISO

Niacinamide inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]]

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

syntaxin 4

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA]

NCBI chr 1:191,880,549...191,890,333
Ensembl chr 1:191,881,559...191,896,774

G

transforming growth factor, beta 1

multiple interactions
increases expression

ISO
EXP

2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein]
Niacinamide results in increased expression of TGFB1 mRNA; Niacinamide results in increased expression of TGFB1 protein

PMID:37120126 PMID:38555046

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta 2

multiple interactions

ISO

Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]]

NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856

G

tumor necrosis factor

multiple interactions
increases expression

EXP
ISO

[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]
Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]; Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA]
Niacinamide results in increased expression of TNF mRNA

PMID:20307516 PMID:21439372 PMID:22385246 PMID:22717288 PMID:24145604 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor superfamily member 11B

decreases expression

ISO

Niacinamide results in decreased expression of TNFRSF11B mRNA

NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075

G

TNF superfamily member 11

decreases expression

ISO

Niacinamide results in decreased expression of TNFSF11 mRNA

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479

G

tumor protein p53

multiple interactions
decreases expression

ISO

[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]; Niacinamide results in increased phosphorylation of and results in increased acetylation of TP53 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]
Niacinamide results in decreased expression of TP53 protein

PMID:12782109 PMID:18482975 PMID:18681908 PMID:25478867 PMID:26712469

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

tyrosinase

increases expression

ISO

Niacinamide results in increased expression of TYR mRNA; Niacinamide results in increased expression of TYR protein

NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:150,527,687...150,622,857

G

uncoupling protein 2

multiple interactions

ISO

Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA]

NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:164,251,373...164,257,743

G

vesicle-associated membrane protein 2

multiple interactions

EXP

[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA]

NCBI chr10:54,292,423...54,296,657
Ensembl chr10:54,292,806...54,296,654

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

multiple interactions

ISO

sirtinol inhibits the reaction [S-allylcysteine results in increased phosphorylation of ACACA protein]

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

aryl hydrocarbon receptor

multiple interactions

ISO

AHR mutant form inhibits the reaction [sirtinol results in increased expression of CYP1A1 mRNA]; AHR mutant form inhibits the reaction [sirtinol results in increased expression of NQO1 mRNA]

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

AKT serine/threonine kinase 1

multiple interactions

ISO

sirtinol inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT1 protein]]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

amyloid beta precursor protein

multiple interactions

ISO

sirtinol inhibits the reaction [cilostazol inhibits the reaction [APP protein results in decreased expression of and results in decreased activity of SIRT1 protein]]

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

BCL2 associated X, apoptosis regulator

multiple interactions

ISO

sirtinol inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of BAX protein]]
sirtinol inhibits the reaction [rhodioloside inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]]; sirtinol promotes the reaction [cudraflavone B results in increased expression of BAX protein]

PMID:23881456 PMID:25665036 PMID:26450947 PMID:28851138

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

ISO

sirtinol inhibits the reaction [rhodioloside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]]; sirtinol promotes the reaction [cudraflavone B results in decreased expression of BCL2 protein]

PMID:23881456 PMID:28851138

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

caspase 3

multiple interactions

ISO
EXP

sirtinol inhibits the reaction [Resveratrol results in increased activity of CASP3 protein]; sirtinol inhibits the reaction [rhodioloside inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]]; sirtinol promotes the reaction [cudraflavone B results in increased activity of CASP3 protein]
sirtinol inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]]; sirtinol results in increased cleavage of and results in increased activity of CASP3 protein
sirtinol inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 protein modified form]]; sirtinol promotes the reaction [Hydrogen Peroxide results in increased expression of CASP3 protein modified form]

PMID:20697895 PMID:23881456 PMID:24889822 PMID:25665036 PMID:26251326 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 9

multiple interactions

ISO

sirtinol inhibits the reaction [resveratrol results in increased activity of CASP9 protein]

Ensembl chr 5:159,391,188...159,409,648

G

C-C motif chemokine ligand 2

multiple interactions

ISO

sirtinol inhibits the reaction [resveratrol inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]]

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 20

increases expression

ISO

sirtinol results in increased expression of CCL20 mRNA

NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:91,836,946...91,839,736

G

CD40 molecule

multiple interactions

ISO

sirtinol promotes the reaction [TNF protein results in increased expression of CD40 mRNA]

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

ISO

sirtinol results in increased expression of CDKN1A mRNA; sirtinol results in increased expression of CDKN1A protein
sirtinol promotes the reaction [cudraflavone B results in increased expression of CDKN1A protein]

PMID:22495798 PMID:23881456

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

ISO

sirtinol promotes the reaction [cudraflavone B results in increased expression of CDKN1B protein]

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

collagen type X alpha 1 chain

decreases expression

ISO

sirtinol results in decreased expression of COL10A1 protein

NCBI chr20:39,737,536...39,744,518
Ensembl chr20:39,716,822...39,751,440

G

collagen type I alpha 1 chain

decreases expression

ISO

sirtinol results in decreased expression of COL1A1 protein

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type II alpha 1 chain

decreases expression

ISO

sirtinol results in decreased expression of COL2A1 protein

NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:130,977,561...131,006,627

G

cytochrome b-245 alpha chain

increases expression

EXP

sirtinol results in increased expression of CYBA mRNA

NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214

G

cytochrome b-245 beta chain

multiple interactions

ISO

sirtinol inhibits the reaction [rhodioloside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of CYBB protein]]

NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
multiple interactions

ISO

sirtinol results in increased expression of CYP1A1 mRNA
AHR mutant form inhibits the reaction [sirtinol results in increased expression of CYP1A1 mRNA]

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

E1A binding protein p300

multiple interactions

ISO

sirtinol inhibits the reaction [cilostazol affects the expression of EP300 protein]; sirtinol inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of EP300 protein]]

PMID:24254769 PMID:25665036

NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574

G

coagulation factor III, tissue factor

multiple interactions

ISO

sirtinol promotes the reaction [TNF protein results in increased expression of F3 mRNA]; sirtinol promotes the reaction [TNF protein results in increased expression of F3 protein]

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369

G

F-box protein 32

multiple interactions

ISO

[sirtinol results in decreased activity of SIRT1 protein] which results in decreased expression of FBXO32 mRNA

NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:91,620,925...91,654,491

G

forkhead box O1

multiple interactions
increases acetylation

ISO
EXP

sirtinol inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased acetylation of FOXO1 protein]]
sirtinol results in increased acetylation of FOXO1 protein
sirtinol inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in increased acetylation of FOXO1 protein]]; sirtinol promotes the reaction [Hydrogen Peroxide results in increased acetylation of FOXO1 protein]

PMID:24889822 PMID:25665036

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

growth hormone 1

multiple interactions
increases secretion
increases expression

EXP

sirtinol inhibits the reaction [resveratrol results in decreased secretion of GH1 protein]
sirtinol results in increased secretion of GH1 protein
sirtinol results in increased expression of GH1 mRNA

NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,727,884...91,729,859

G

insulin-like growth factor 1 receptor

decreases expression

ISO

sirtinol results in decreased expression of IGF1R mRNA

NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664

G

insulin-like growth factor binding protein 3

increases expression

ISO

sirtinol results in increased expression of IGFBP3 mRNA

NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944

G

interleukin 1 beta

multiple interactions
increases expression

ISO

sirtinol inhibits the reaction [resveratrol inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]]
sirtinol inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]
sirtinol results in increased expression of IL1B mRNA

PMID:20531350 PMID:22385246 PMID:23973301

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

KLF transcription factor 2

multiple interactions

ISO

sirtinol inhibits the reaction [resveratrol results in increased expression of KLF2 mRNA]

NCBI chr16:17,555,136...17,557,768
Ensembl chr16:17,555,136...17,557,768

G

kallikrein 1-related peptidase C10

decreases expression
multiple interactions

ISO

sirtinol results in decreased expression of KLK3 mRNA; sirtinol results in decreased expression of KLK3 protein
sirtinol inhibits the reaction [Estradiol results in increased expression of KLK3 mRNA]

NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586

G

mitogen activated protein kinase 1

decreases phosphorylation

ISO

sirtinol results in decreased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

decreases phosphorylation

ISO

sirtinol results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

microRNA 141

multiple interactions

EXP

sirtinol affects the reaction [MIR141 mRNA affects the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of NOS1 protein]]; sirtinol affects the reaction [MIR141 mRNA affects the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of SNCA protein]]

NCBI chr 4:159,209,525...159,209,618

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

EXP

sirtinol inhibits the reaction [resveratrol results in decreased expression of MYC protein]

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

Nanog homeobox

multiple interactions

ISO

sirtinol inhibits the reaction [cordycepin results in increased expression of NANOG mRNA]

NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:157,615,687...157,623,061

G

NFE2 like bZIP transcription factor 2

multiple interactions

EXP

sirtinol inhibits the reaction [resveratrol results in increased expression of NFE2L2 protein]

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

NFKB inhibitor alpha

increases degradation

ISO

sirtinol results in increased degradation of NFKBIA protein

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

NK3 homeobox 1

decreases expression

ISO

sirtinol results in decreased expression of NKX3-1 mRNA

NCBI chr15:50,883,661...50,886,253
Ensembl chr15:50,883,597...50,886,251

G

nitric oxide synthase 1

multiple interactions

EXP

sirtinol affects the reaction [MIR141 mRNA affects the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of NOS1 protein]]

NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837

G

NADPH oxidase 4

multiple interactions
increases expression

EXP

resveratrol inhibits the reaction [sirtinol results in increased expression of NOX4 mRNA]

NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression

ISO

AHR mutant form inhibits the reaction [sirtinol results in increased expression of NQO1 mRNA]

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions

ISO

sirtinol inhibits the reaction [resveratrol results in increased expression of NR0B2 mRNA]

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475

G

pyruvate dehydrogenase kinase 1

multiple interactions

EXP

sirtinol inhibits the reaction [resveratrol results in decreased expression of PDK1 protein]

NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:77,113,473...77,144,145

G

pyruvate dehydrogenase kinase 4

multiple interactions

ISO

sirtinol inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of PDK4 protein]]

NCBI chr 4:34,558,327...34,568,329
Ensembl chr 4:34,556,330...34,568,381

G

3-phosphoinositide dependent protein kinase-1

multiple interactions

ISO

sirtinol inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in decreased expression of PDPK1 protein]]

NCBI chr10:13,610,000...13,687,226
Ensembl chr10:13,610,063...13,679,181

G

POU class 5 homeobox 1

multiple interactions

ISO

sirtinol inhibits the reaction [cordycepin results in increased expression of POU5F1 mRNA]

NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598

G

PPARG coactivator 1 alpha

multiple interactions

ISO
EXP

sirtinol inhibits the reaction [Melatonin inhibits the reaction [Cadmium Chloride results in increased acetylation of PPARGC1A protein]]; sirtinol inhibits the reaction [Melatonin inhibits the reaction [Cadmium results in increased acetylation of PPARGC1A protein]]
sirtinol inhibits the reaction [genipin inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of PPARGC1A protein]]
sirtinol inhibits the reaction [resveratrol results in increased expression of PPARGC1A protein]

PMID:24395567 PMID:25159133 PMID:28477916

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions

ISO

sirtinol inhibits the reaction [genipin inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of PRKN protein]]

NCBI chr 1:51,236,410...52,430,242
Ensembl chr 1:51,210,330...52,430,304

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

sirtinol inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

RB transcriptional corepressor 1

multiple interactions

ISO

sirtinol promotes the reaction [cudraflavone B results in decreased phosphorylation of RB1 protein]

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases localization

ISO

sirtinol inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased acetylation of RELA protein]]
sirtinol promotes the reaction [TNF protein results in increased acetylation of RELA protein]
sirtinol results in increased localization of RELA protein

PMID:21745208 PMID:22717288 PMID:23257246

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

SHC adaptor protein 1

multiple interactions
increases expression

ISO

sirtinol inhibits the reaction [SIRT1 protein binds to SHC1 promoter]
sirtinol results in increased expression of SHC1 mRNA; sirtinol results in increased expression of SHC1 protein

NCBI chr 2:177,135,649...177,147,257
Ensembl chr 2:177,135,659...177,147,914

G

sirtuin 1

decreases activity
multiple interactions

ISO
EXP

sirtinol analog results in decreased activity of SIRT1 protein; sirtinol results in decreased activity of SIRT1 protein
sirtinol inhibits the reaction [cobaltous chloride results in increased expression of SIRT1 protein]; sirtinol inhibits the reaction [Resveratrol results in increased expression of and results in increased activity of SIRT1 protein]
[sirtinol results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Glucose; sirtinol inhibits the reaction [cilostazol inhibits the reaction [APP protein results in decreased expression of and results in decreased activity of SIRT1 protein]]; sirtinol inhibits the reaction [cilostazol results in increased phosphorylation of SIRT1 protein]; sirtinol inhibits the reaction [genipin inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in decreased expression of SIRT1 protein]]; sirtinol inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in decreased activity of SIRT1 protein]]; sirtinol inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein]]
[sirtinol results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; [sirtinol results in decreased activity of SIRT1 protein] which results in decreased expression of FBXO32 mRNA; [sirtinol results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Plant Extracts; [sirtinol results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Resveratrol; [sirtinol results in decreased activity of SIRT1 protein] which results in increased susceptibility to Hydrogen Peroxide; sirtinol inhibits the reaction [[Resveratrol co-treated with TNF protein] results in increased expression of SIRT1 protein]; sirtinol inhibits the reaction [cordycepin results in increased expression of SIRT1 mRNA]; sirtinol inhibits the reaction [cudraflavone B results in increased expression of SIRT1 mRNA]; sirtinol inhibits the reaction [cudraflavone B results in increased expression of SIRT1 protein]; sirtinol inhibits the reaction [Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of and results in decreased activity of SIRT1 protein]]; sirtinol inhibits the reaction [Melatonin inhibits the reaction [Cadmium results in decreased expression of and results in decreased activity of SIRT1 protein]]; sirtinol inhibits the reaction [SIRT1 protein binds to SHC1 promoter]

PMID:16302818 PMID:18681908 PMID:19288225 PMID:20370652 PMID:20531350 More...

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

sirtuin 2

decreases activity

ISO

sirtinol analog results in decreased activity of SIRT2 protein; sirtinol results in decreased activity of SIRT2 protein

PMID:16302818 PMID:24998427

NCBI chr 1:93,181,472...93,204,499
Ensembl chr 1:93,181,224...93,204,499

G

SMAD family member 1

decreases phosphorylation

ISO

sirtinol results in decreased phosphorylation of SMAD1 protein

NCBI chr19:45,417,430...45,477,962
Ensembl chr19:45,417,433...45,477,957

G

SMAD family member 5

decreases phosphorylation

ISO

sirtinol results in decreased phosphorylation of SMAD5 protein

NCBI chr17:7,867,640...7,896,983
Ensembl chr17:7,871,984...7,890,992

G

SMAD family member 9

decreases phosphorylation

ISO

sirtinol results in decreased phosphorylation of SMAD9 protein

NCBI chr 2:141,106,668...141,156,477
Ensembl chr 2:141,106,668...141,156,477

G

synuclein alpha

multiple interactions

EXP

sirtinol affects the reaction [MIR141 mRNA affects the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of SNCA protein]]

NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:91,026,474...91,126,315

G

SRY-box transcription factor 2

multiple interactions

ISO

sirtinol inhibits the reaction [cordycepin results in increased expression of SOX2 mRNA]

NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350

G

sequestosome 1

multiple interactions

EXP

sirtinol inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in increased expression of SQSTM1 protein]]; sirtinol promotes the reaction [Hydrogen Peroxide results in increased expression of SQSTM1 protein]

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

sterol regulatory element binding transcription factor 1

multiple interactions

ISO

sirtinol inhibits the reaction [S-allylcysteine results in decreased expression of SREBF1 protein]

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

tumor necrosis factor

multiple interactions
increases expression

ISO
EXP

sirtinol inhibits the reaction [[resveratrol co-treated with TNF protein] results in increased expression of SIRT1 protein]; sirtinol inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased acetylation of RELA protein]]; sirtinol inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; sirtinol promotes the reaction [TNF protein results in increased expression of F3 mRNA]; sirtinol promotes the reaction [TNF protein results in increased expression of F3 protein]
Sirtinol promotes the reactions [Lipopolysaccharide, acetate, acetaldehyde increases secretion of Tnf protein from Kupffer cells]
sirtinol inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; sirtinol promotes the reaction [TNF protein results in increased acetylation of RELA protein]; sirtinol promotes the reaction [TNF protein results in increased expression of CD40 mRNA]
sirtinol results in increased expression of TNF mRNA

CTD
RGD

PMID:20978007 PMID:22385246 PMID:22717288 PMID:23257246 PMID:23973301 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

tumor protein p53

multiple interactions

ISO

[sirtinol results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; sirtinol promotes the reaction [arsenic disulfide results in increased expression of and results in increased phosphorylation of TP53 protein]; sirtinol promotes the reaction [cudraflavone B results in increased expression of TP53 protein]
sirtinol inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]]

PMID:18298901 PMID:18681908 PMID:23881456 PMID:25665036

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

tripartite motif containing 63

multiple interactions

ISO

sirtinol inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of TRIM63 protein]]

PMID:25665036 PMID:26450947

NCBI chr 5:151,817,209...151,831,026
Ensembl chr 5:151,817,225...151,831,058

G

ubiquitin specific peptidase 7

multiple interactions

ISO

sirtinol inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of USP7 protein]]

NCBI chr10:7,335,508...7,432,018
Ensembl chr10:7,367,604...7,432,013

G

vascular endothelial growth factor A

multiple interactions

EXP

[sirtinol co-treated with cobaltous chloride] results in increased cleavage of VEGFA protein; sirtinol inhibits the reaction [cobaltous chloride results in increased secretion of VEGFA protein]

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

multiple interactions

ISO

[splitomicin results in decreased activity of SIRT1 protein] inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein]; [splitomicin results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in increased phosphorylation of ACACA protein]

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

caspase 3

multiple interactions

ISO

splitomicin promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

coagulation factor II, thrombin

multiple interactions

ISO

splitomicin promotes the reaction [F2 protein results in increased expression of F3 protein]

NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246

G

coagulation factor III, tissue factor

multiple interactions

ISO

[Histamine co-treated with splitomicin] results in increased expression of F3 protein; splitomicin promotes the reaction [F2 protein results in increased expression of F3 protein]; splitomicin promotes the reaction [TNF protein results in increased expression of F3 mRNA]; splitomicin promotes the reaction [TNF protein results in increased expression of F3 protein]

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369

G

fatty acid binding protein 4

multiple interactions

ISO

splitomicin promotes the reaction [resveratrol results in decreased expression of FABP4 mRNA]; splitomicin promotes the reaction [resveratrol results in decreased expression of FABP4 protein]

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

potassium voltage-gated channel subfamily A member 5

decreases expression

EXP

splitomicin results in decreased expression of KCNA5 mRNA

NCBI chr 4:161,040,853...161,044,311
Ensembl chr 4:160,996,950...161,044,408

G

kallikrein B1

increases response to substance
multiple interactions

ISO

KLKB1 gene mutant form results in increased susceptibility to splitomicin
splitomicin inhibits the reaction [KLKB1 gene mutant form results in decreased susceptibility to Rose Bengal]

NCBI chr16:53,690,180...53,714,570
Ensembl chr16:53,691,220...53,716,339

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

splitomicin promotes the reaction [resveratrol results in decreased expression of PPARG mRNA]; splitomicin promotes the reaction [resveratrol results in decreased expression of PPARG protein]

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

PPARG coactivator 1 alpha

multiple interactions

EXP

splitomicin inhibits the reaction [[Nitrites co-treated with Oxygen deficiency] results in increased expression of PPARGC1A mRNA]

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

splitomicin promotes the reaction [TNF protein results in increased localization of and results in decreased acetylation of and results in increased activity of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

sirtuin 1

decreases activity
multiple interactions
decreases expression

ISO
EXP

splitomicin results in decreased activity of SIRT1 protein
[splitomicin results in decreased activity of SIRT1 protein] inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein]; [splitomicin results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in increased phosphorylation of ACACA protein]
splitomicin results in decreased expression of SIRT1 mRNA

PMID:18482975 PMID:20978007 PMID:25447406

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

transferrin

increases activity

ISO

splitomicin results in increased activity of TF protein

NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:112,647,642...112,695,400

G

tumor necrosis factor

multiple interactions

ISO

splitomicin promotes the reaction [TNF protein results in increased expression of F3 mRNA]; splitomicin promotes the reaction [TNF protein results in increased expression of F3 protein]; splitomicin promotes the reaction [TNF protein results in increased localization of and results in decreased acetylation of and results in increased activity of RELA protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	20874
role	20844
biological role	20831
biochemical role	19888
enzyme inhibitor	18710
EC 3.* (hydrolase) inhibitor	17214
EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor	15467
EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor	15467
EC 3.5.1.98 (histone deacetylase) inhibitor	15214
Sir2 inhibitor	186
nicotinamide	149
sirtinol	65
splitomicin	13
tenovin-6	0

paths to the root